We are live on ! Find out more
FBRX icon

Forte Biosciences

33 hedge funds and large institutions have $2.85M invested in Forte Biosciences in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,850% more call options, than puts

Call options by funds: $119K | Put options by funds: $2K

0.1% less ownership

Funds ownership: 0.63%0.53% (-0.1%)

5% less capital invested

Capital invested by funds: $3.01M → $2.85M (-$152K)

15% less funds holding

Funds holding: 3933 (-6)

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

Holders
33
Holders Change
-6
Holders Change %
-15.38%
% of All Funds
0.57%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
8
Reduced
11
Closed
10
Calls
$119K
Puts
$2K
Net Calls
+$117K
Net Calls Change
+$1.29M

FBRX Hedge Fund Activity: Q3 2022 in Review

33 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q3 2022, worth a combined $2.85M — down 5.1% from $3.01M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of FBRX and 4 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 8 added.

The largest buyer was Newtyn Management, opening a new position worth an estimated $635K. The largest seller was Morgan Stanley, cutting an estimated $427K.

  • 33 institutional investors held Forte Biosciences (FBRX) as of Q3 2022, down from 39 in Q2 2022.
  • Funds reported $2.85M of Forte Biosciences stock for Q3 2022, down 5.1% quarter-over-quarter.
  • 4 funds opened new Forte Biosciences positions in Q3 2022 and 10 closed out, a net change of -6 holders.
  • The largest Forte Biosciences buyer in Q3 2022 was Newtyn Management, an estimated $635K added.
  • The largest Forte Biosciences seller in Q3 2022 was Morgan Stanley, an estimated $427K sold.

Based on aggregated 13F filings for Q3 2022.